Toni K. Choueiri
Harvard University(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Renal and related cancers, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → The Immune Landscape of Cancer(2018)6,070 cited
- → Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma(2015)5,839 cited
- → Post-acute COVID-19 syndrome(2021)4,909 cited
- → Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma(2018)4,536 cited
- → Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma(2017)3,352 cited
- → Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)2,502 cited
- → Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study(2009)